Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface,
predominantly caused by prior asbestos exposure. There is a global epidemic of malignant …

Malignant mesothelioma is an aggressive tumor of serosal surfaces, such as the pleura and
the peritoneum. This tumor was once rare, but its incidence is increasing worldwide …

Purpose To provide evidence-based recommendations to practicing physicians and others
on the management of malignant pleural mesothelioma. Methods ASCO convened an …

Malignant mesothelioma is an aggressive, treatment-resistant tumour, which is increasing in
frequency throughout the world. Although the main risk factor is asbestos exposure, a virus …

Background: The growth pattern of malignant pleural mesothelioma makes the use of
RECIST (response evaluation criteria in solid tumours) response criteria difficult. We have …

Malignant pleural mesothelioma (MPM) is a deadly disease that occurs in 2,000 to 3,000
people each year in the United States. Although MPM is an extremely difficult disease to …

Background: The aim of this multicenter trial was to prospectively evaluate neo-adjuvant
chemotherapy followed by extrapleural pneumonectomy (EPP) and radiotherapy, including …

Purpose Gemcitabine plus cisplatin is active in malignant mesothelioma (MM), although
single-arm phase II trials have reported variable outcomes. Vascular endothelial growth …

Purpose This multicenter, phase III study compared overall survival (OS) of second-line
pemetrexed plus best supportive care (BSC) versus BSC alone in patients with advanced …

Introduction Malignant pleural mesothelioma poses unique difficulties in tumor
measurement and response assessment; however, robust and reproducible assessment of …